Research · Sep 3, 2026
[APLS] Apellis Pharmaceuticals Compounds Biopharma Franchise Through Complement Therapies And Launch
Apellis Pharmaceuticals, Inc. is a Waltham, Massachusetts-headquartered commercial-stage biopharmaceutical company focused on the complement system, a part of the immune system that when dysregulated is implicated in a range of diseases. The business is built around the complement-therapy products, with the company having approved products that address the geographic atrophy, a form of the advanced age-related macular degeneration affecting the retina, and the paroxysmal nocturnal hemoglobinuria, a rare blood disorder, and the company commercializes these products and continues to develop the complement-focused pipeline across additional indications. The revenue is generated from the sale of the complement-therapy products, and the economics reflect the commercial-stage profile with the product revenue from the launched products, the substantial investment in the commercialization and the research and development, and the path toward the sustained profitability. On selected various aggregate disclosure, the fiscal 2025 financial profile reflects total revenue derived from the sale of the complement-therapy products, an operating profile reflecting a commercial-stage biopharmaceutical company, and a balance-sheet position reflecting the capital requirements of a company in the commercial-launch and development phase. The complement-therapy commercial core franchise anchors revenue, supported by the approved products producing the revenue from the geographic-atrophy and paroxysmal-nocturnal-hemoglobinuria indications, by the complement-system platform providing the scientific basis for the products and pipeline, and by the commercial infrastructure supporting the launch. The multi-cycle commercial-launch ramp combined with the pipeline drives the multi-year trajectory, with the commercial-launch ramp reflecting the trajectory of the commercialization and uptake of the approved products particularly in the geographic-atrophy indication, and the pipeline reflecting the development of the additional indications and candidates that apply the complement platform. Capital structure reflects the capital requirements of a commercial-stage biopharmaceutical company, and a capital allocation framework focused on the commercialization, the pipeline, and the balance-sheet management. The bull case anchors on the approved complement-therapy products, the commercial-launch ramp, and the pipeline optionality; the bear case anchors on the commercial-execution and competition considerations, the path to the sustained profitability, and the clinical and regulatory uncertainty.